VINCERX PHARMA INC by Vincerx Pharma, Inc. Analyst Price Targets - Benzinga

SPY752.16−0.29%QQQ681.66−0.53%BTC/USD76,624.47−0.93%DIA515.40−0.32%GLD360.39+0.32%TLT81.29+0.22%

Premium Services

VINCERX PHARMA INC by Vincerx Pharma, Inc.

VINCOTCEM

Trade with Public

Trade with Public

$0.0150

-0.085-85%

Last update: Oct 29, 9:30 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

VINCERX PHARMA INC by Vincerx Pharma, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for VINCERX PHARMA INC by Vincerx Pharma, Inc. (VINC).

Price Target Range — 1 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingOutperform# Analysts2Avg. Consensus PT$40Upside to Avg. PT+266566.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2024	Leerink Partners	Jonathan Chang	PT Cut	Outperform	$80→$40
Apr 9, 2024	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—
Apr 1, 2024	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—

Analyst Ratings News

US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert

U.S. stock futures declined on Monday after a holiday-shortened week that ended with a mixed close on Thursday.

Rishabh Mishra

US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert

US. stock futures rose on Monday following Friday's advances. Futures of all fourth benchmark indices rose in premarket trading.

Rishabh Mishra

PRO
Leerink Partners Maintains Outperform on Vincerx Pharma, Lowers Price Target to $2

Leerink Partners analyst Jonathan Chang maintains Vincerx Pharma (NASDAQ:VINC) with a Outperform and lowers the price target from $4 to $2.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Vincerx Pharma

Cantor Fitzgerald analyst Li Watsek reiterates Vincerx Pharma (NASDAQ:VINC) with a Overweight.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Vincerx Pharma

Cantor Fitzgerald analyst Li Watsek reiterates Vincerx Pharma (NASDAQ:VINC) with a Overweight.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Vincerx Pharma, Maintains $5 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates Vincerx Pharma (NASDAQ:VINC) with a Overweight and maintains $5 price target.

Benzinga Newsdesk